After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Verona Pharma Plc ADR is $3.24B. A total of 0.7 million shares were traded on the day, compared to an average of 1.05M shares.
In the most recent transaction, Hahn Mark W sold 1,600 shares of VRNA for 5.00 per share on Nov 25 ’24. After the transaction, the Chief Financial Officer now owns 14,289,736 company shares. In a previous transaction on Nov 26 ’24, Hahn Mark W sold 800 shares at 5.00 per share. VRNA shares that Chief Financial Officer owns now total 14,288,936.
Among the insiders who sold shares, ZACCARDELLI DAVID disposed of 1,600 shares on Nov 25 ’24 at a per-share price of $5.00. This resulted in the President and CEO holding 15,200,752 shares of VRNA after the transaction. In another insider transaction, Rickard Kathleen A. sold 240,000 shares at $4.90 per share on Nov 25 ’24. Company shares held by the Chief Medical Officer now total 2,671,480.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, VRNA has a high of $40.13 and a low of $11.39.
As of this writing, VRNA has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 6.0 estimates, with a high estimate of -$0.04 per share and a lower estimate of -$0.54. The company reported an EPS of -$0.02 in the last quarter
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $1.59, while its Total Shareholder’s Equity was $148.00M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 5.00.
